Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
52.4M
-
Number of holders
-
115
-
Total 13F shares, excl. options
-
46M
-
Shares change
-
-768K
-
Total reported value, excl. options
-
$135M
-
Value change
-
-$4.18M
-
Put/Call ratio
-
0.17
-
Number of buys
-
44
-
Number of sells
-
-43
-
Price
-
$2.94
Significant Holders of 2seventy bio, Inc. - Common Stock (TSVT) as of Q4 2024
134 filings reported holding TSVT - 2seventy bio, Inc. - Common Stock as of Q4 2024.
2seventy bio, Inc. - Common Stock (TSVT) has 115 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 46M shares
of 52.4M outstanding shares and own 87.68% of the company stock.
Largest 10 shareholders include Kynam Capital Management, LP (5.95M shares), GOLDMAN SACHS GROUP INC (4.29M shares), BlackRock, Inc. (4.22M shares), VANGUARD GROUP INC (3.76M shares), MORGAN STANLEY (2.92M shares), Newtyn Management, LLC (2.53M shares), BANK OF AMERICA CORP /DE/ (2.52M shares), BAKER BROS. ADVISORS LP (2.5M shares), Casdin Capital, LLC (2M shares), and REGENERON PHARMACEUTICALS, INC. (1.25M shares).
This table shows the top 115 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.